1. Home
  2. Analysis
  3. Yervoy
  4. Deafness-bilateral

Yervoy and Deafness bilateral - a phase IV clinical study of FDA data

Summary:

Deafness bilateral is reported as a side effect among people who take Yervoy (ipilimumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Opdivo, and have Metastatic malignant melanoma.

The phase IV clinical study analyzes which people have Deafness bilateral when taking Yervoy. It is created by eHealthMe based on reports of 26,647 people who have side effects when taking Yervoy from the FDA, and is updated regularly.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

What is Deafness bilateral?

Deafness bilateral is found to be associated with 208 drugs and 741 conditions by eHealthMe. Check the latest studies of Deafness bilateral.

On Apr, 25, 2026

26,647 people reported to have side effects when taking Yervoy.
Among them, 12 people (0.05%) have Deafness bilateral.

Could Yervoy cause Deafness bilateral?

Among these 12 people:

How long have people been on Yervoy when they have Deafness bilateral? *

  • < 1 month: 20 %
  • 1 - 6 months: 80 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Deafness bilateral when taking Yervoy? *

  • female: 41.67 %
  • male: 58.33 %

What is the age of people who have Deafness bilateral when taking Yervoy? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 20 %
  • 60+: 80 %

What are other drugs people take besides Yervoy? *

  1. Opdivo: 9 people, 75.00%
  2. Lasix: 2 people, 16.67%
  3. Crestor: 2 people, 16.67%
  4. Coreg: 2 people, 16.67%
  5. Aldactone: 2 people, 16.67%
  6. Keytruda: 1 person, 8.33%
  7. Calcium: 1 person, 8.33%
  8. Asa: 1 person, 8.33%

What are other side effects people have besides Deafness bilateral? *

  1. Dizziness: 5 people, 41.67%
  2. Balance Disorder: 3 people, 25.00%
  3. Uveitis (inflammation of the uvea): 2 people, 16.67%
  4. Speech Impairment (Adult) (inability to speak (adult)): 2 people, 16.67%
  5. Ototoxicity (damage to the ear): 2 people, 16.67%
  6. Malignant Neoplasm Progression (cancer tumour came back): 2 people, 16.67%
  7. Vision Blurred: 2 people, 16.67%
  8. Hepatic Enzyme Increased: 2 people, 16.67%
  9. Weakness: 1 person, 8.33%
  10. Gait Disturbance: 1 person, 8.33%

What are the existing conditions these people have? *

  1. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 8 people, 66.67%
  2. Malignant Melanoma (skin cancer rises from melancytes): 5 people, 41.67%
  3. Pain: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Yervoy and have Deafness bilateral?

- Check whether Deafness bilateral is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Yervoy:

Deafness bilateral treatments and more:

How severe was Deafness bilateral and when was it recovered:

Expand to all the drugs that have ingredients of ipilimumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Yervoy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deafness bilateral:

Browse all the conditions that are associated with Deafness bilateral:

How the study uses the data?

The study uses data from the FDA. It is based on ipilimumab (the active ingredients of Yervoy) and Yervoy (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.